Navigation Links
Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
Date:9/30/2013

A from tumors and improve perfusion and drug delivery to the tumor bed. The data from this trial suggest that similar processes may be occurring in patients as well and that patients with high levels of HA may derive the most treatment benefit from PEGPH20 combination therapy," stated Sunil R. Hingorani, M.D., Ph.D., Associate Member of the Clinical Research and Public Health Divisions at Fred Hutchinson Cancer Research Center and lead investigator for this study. "Pancreatic cancer is a devastating disease, and these data provide intriguing evidence for a new treatment paradigm. We look forward to the results for PEGPH20 in large randomized Phase 2 trials with the most active chemotherapy regimens available to definitively establish the potential benefit of this strategy and correlation with HA status."

Additional Study Details

This study enrolled 28 patients with stage IV treatment naïve pancreatic ductal adenocarcinoma. Patients were treated with one of three doses of PEGPH20 (1.0, 1.6 and 3.0 µg/kg twice weekly for four weeks, then weekly thereafter) in combination with gemcitabine 1000 mg/m2 administered intravenously. The overall response rate (ORR) (complete response + partial response) by RECIST 1.1 criteria was 42 percent (10 of 24 patients, 95 percent CI 22 – 62 percent) in the intent to treat population for those treated at therapeutic dose levels of PEGPH20 (1.6 and 3.0 µg/kg). Additionally, 43 percent of evaluable patients saw a reduction of at least 70 percent in serum carbohydrate antigen 19-9 (CA 19-9), a biomarker of tumor cell burden.1 In the intent to treat population, 17 patients had biopsies evaluable for HA scoring. The method of HA scoring was prospectively defined for tumor-cell associated and stromal associated tissue, and assessed by central pathology laboratory evaluation. The ORR in patients with tumor-cell associated high HA was 83 percent, indicating
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
2. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
3. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
4. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
5. Halozyme Reports Second Quarter 2013 Financial Results
6. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
7. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
8. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
9. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
10. Halozyme Reports First Quarter 2013 Financial Results
11. Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... BOSTON , July 6, 2015 ... Inc. (NASDAQ: ISIS ), announced today that ... Orphan Drug Designation to volanesorsen (ISIS-APOCIII Rx ) ... Syndrome (FCS).  FCS is a rare genetic disease ... of pancreatitis. In a Phase 2 study published ...
(Date:7/5/2015)... 6, 2015 Nihon University is pleased ... on Medical-Engineering Collaboration "Medicine Definitely Jumps Up with ... in Tokyo, Japan . Many ... research will present their achievements and future prospects ... industry produced with 8K technology. (Documentation: ...
(Date:7/3/2015)... 4, 2015 Un fournisseur ... que sont l,hypertension, le diabète et les troubles ... l,intermédiaire de plateformes éducatives gratuites et d,une conférence ... (Photo: http://photos.prnewswire.com/prnh/20150630/227090 ) , ... en ligne , Prendre en charge l,hypertension ...
Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3
... 23, 2007 -,Gentium S.p.A. (NASDAQ: GENT) (the ... will be the subject of a poster,presentation ... being held in,Rio de Janeiro, Brazil from ... 2007, Cinara Echart, Ph.D., Manager of,Biological Research ...
... 24 /CNW/ - The weight loss medication Xenical,(orlistat ... such as blood pressure, glycaemic,control and lipid profile ... and hypertension, according to a study analysis,presented at ... ,This analysis strengthens the wealth of data already ...
Cached Medicine Technology:Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology 2Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology 3New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 2New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 3New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 4New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 5New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 6
(Date:7/6/2015)... ... , ... In a split second, breaking a bone can cause loss of ... fracture through the bone health screenings conducted by American Bone Health trained Peer Educators ... residents need this information to remain independent and strong for many more years,” according ...
(Date:7/6/2015)... ... , ... World renowned Los Angeles facial plastic surgeon , Dr. Paul ... treatment solutions. Individuals that want to make multiple changes to their facial appearance are ... each of their needs. , "Anytime I see an opportunity to change the ...
(Date:7/6/2015)... ... July 06, 2015 , ... Orthopaedic & Spine ... 100th case using SpineFrontier’s® PedFuse® REmind® Screws. The operation took place on Tuesday, ... The procedure was an L5-S1 posterior lumbar interbody fusion on a 69 year ...
(Date:7/6/2015)... ... ... The Path of Least Resistance: The Evolution of Capitalism and Politics in America ... the past 40 years. The book explores the evolution of the global economy and ... time capsule that chronicles the economic development of the United States — from its ...
(Date:7/5/2015)... ... July 05, 2015 , ... Women's Excellence in ... in Lake Orion. These classes are geared towards families that want their children ... break. , The fitness class will take place TUESDAYS at 4:30pm. Questions? ...
Breaking Medicine News(10 mins):Health News:National Bone Health Screening and Awareness Day 2Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:New Book Brings Reveals The Repercussions Associated With The Global Economy 2
... same breast cancer treatments as Hispanic and white women ... were more likely to be diagnosed// with later-stage cancer ... ,For the study, lead researcher Wendy ... Cancer Center and colleagues examined 2,140 women participating in ...
... weight loss drugs are really safe, an analysis of previous ... was conducted. What// came to light was the lack of ... ,Two Canadian researchers, Raj Padwal and Sumit Majumdar of ... like sibutramine (Meridia), orlistat (Xenical) and rimonabant (Acomplia) are no ...
... near toxic waste may make you diabetic, says a study ... 1993 and 2000.// ,Type-two diabetes has seen a ... from 1980 to 2002. While scientists scramble to find explanations ... the growing diabetes rate. , ,However, the study by ...
... Carolina State University toxologists and Rice University Chemists// has ... intake speed of nanoparticles through the skin. Vitro experiments ... of the research. These bucky balls contained amino acids. ... with the increasing degree of flexing of the skin. ...
... and Prevention (CDC) Atlanta's Division of Tuberculosis Elimination feel ... and made TB tests mandatory for all foreign-born nationals, ... ,Tuberculosis can only be eradicated if all ... necessary, treated for latent TB infection, they say. ...
... Dentists at the Manchester University have developed a new ... x-rays//. This is done by automatically measuring the width ... ,Professor Keith Horner and Dr Hugh Devlin at ... modeling’ technology that was developed by the Division of ...
Cached Medicine News:Health News:Living Near Toxic Waste May Bring On Diabetes 2Health News:Nanoparticle Uptake Zoom by Repetitive Motion 2Health News:All Foreign-born Nationals In US To Be Tested For TB 2
Inquire...
Superior imaging through a 410,000 pixel CCD, unseen color replication from a digital signal processor in the scope, and the added benefit of four way tip deflection make the TF410 a superior choice ...
The computer-optimized optical design produces large, brilliant images of high resolution....
ACMI™ Distortion-Free Laparoscopes utilize technical advances in optical lens design to provide images without the fish-eye effect typically found on the peripheral viewing edges of conventional...
Medicine Products: